Effect of statins on IL-10 signaling and production by chronic lymphocytic leukemia cells
The Journal of Immunology · 2025
DOI: 10.1093/jimmun/vkaf103 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Guizhi Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Biology Platform, Sunnybrook Research Institute, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Interleukin-10, Signal Transduction, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CIHR, Leukemia and Lymphoma Society of Canada, Cancer Research Society.
Abstract (Originalsprache)
The cytokine-signaling inhibitor ruxolitinib causes disease flares of chronic lymphocytic leukemia (CLL). This tumor-promoting activity correlates with its ability to inhibit interleukin (IL)-10 production by CLL B cells that have been activated with IL-2 and the Toll-like receptor 7 (TLR7) agonist resiquimod (called 2S cells) in vitro. In TLR-activated normal human B cells, IL-10 production is regulated by cholesterol biosynthesis and can be inhibited by statins. The goal of this study was to determine if statins affect IL-10 production by 2S cells. Lipophilic statins decreased IL-10 production from 2S CLL cells by inhibiting activation of MYC along with secondary signaling events that amplify and maintain IL10 transcription. IL-10 production was restored when the prenylation defect imposed by statins was corrected by adding geranylgeranyl pyrophosphate. CLL cells activated by ruxolitinib in vivo were enriched with genes associated with prenylation inhibition in TLR-activated human B cells in vitro. These findings suggest IL-10 production by 2S-activated CLL cells is regulated by cholesterol biosynthesis in part through geranylgeranyl pyrophosphate production and substrate prenylation. If IL-10 production in the 2S model constitutes a surrogate test for drug responses in vivo, realization of the potential clinical benefits of statins in CLL may require coadministration of other agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biology Platform, Sunnybrook Research Institute, Toronto, Ontario, Canada.
- Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
- Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada.
- Department of Biochemistry and Molecular Biology, Dalhousie University, Halifax, Nova Scotia, Canada.
- Department of Hematology, Odette Cancer Center, Toronto, Ontario, Canada.
ORCID-Profile: Aditya Surya
Förderung
- CIHR
- Leukemia and Lymphoma Society of Canada
- Cancer Research Society
- Canadian Institutes of Health Research
Zitieren
APA
Wang, G., Luo, T. Y., Shi, Y., Surya, A., Zein, H. S., Fairn, G. D., & Spaner, D. E. (2025). Effect of statins on IL-10 signaling and production by chronic lymphocytic leukemia cells. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf103
Vancouver
Wang G, Luo TY, Shi Y, Surya A, Zein HS, Fairn GD, et al. Effect of statins on IL-10 signaling and production by chronic lymphocytic leukemia cells. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkaf103
BibTeX
@article{Wang2025,
author = {Wang, Guizhi and Luo, Tina YuXuan and Shi, Yonghong and Surya, Aditya and Zein, Haggag S and Fairn, Gregory D and Spaner, David E},
title = {Effect of statins on IL-10 signaling and production by chronic lymphocytic leukemia cells},
journal = {The Journal of Immunology},
year = {2025},
doi = {10.1093/jimmun/vkaf103}
}
EUVIMED